Prana Biotechnology (PRAN +2.6%) gains today after announcing that the Journal of Huntington's...
Thursday, December 13, 2012, 2:37 PM ETPrana Biotechnology (PRAN +2.6%) gains today after announcing that the Journal of Huntington's Disease has published data showing the benefits of its experimental drug PBT2, for the treatment of Huntington's Disease. The results highlight PBT2's ability to inhibit the development of the symptoms and pathological features of the disease in animal models. The drug is being tested on patients in 20 sites across the USA and Australia, with results expected in Q213.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles